The global mucormycosis treatment market is anticipated to grow at a considerable CAGR of 6.5% during the forecast period (2022-2028). The increasing disease prevalence for mucormycosis infections across the globe is one of the prime factors affecting and driving the market for mucormycosis treatment. For instance, as per the information provided by the Government of India around 40,845 cases of mucormycosis or black fungus were detected in 2020. Mucormycosis is considered a rapidly progressive and life-threatening invasive fungal disease. It mainly affects those with organ and bone marrow transplantation along with hematological malignancy and patients with diabetes, cancer, neutropenia, and skin trauma.
Browse the full report description of “Global Mucormycosis Treatment Market Size, Share & Trends Analysis Report By Diagnosis (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Tissue Biopsy), By Treatment (Surgery and Antifungal Drugs), and By End-User (Hospitals & Clinics, and Research Institutes) Forecast, 2022-2028” at https://www.omrglobal.com/industry-reports/mucormycosis-treatment-market
Moreover, to gain on the opportunity key players operating in the global mucormycosis treatment Market had been adopting strategies such as new launches to achieve major market share. For instance, in June 2021, Celon Laboratories which is considered one of the specialty biopharmaceutical manufacturers had introduced Amphotericin B Emulsion, for the treatment of Mucormycosis, which is commonly known as Black Fungus. Additionally, Amphotericin B is considered crucial to give an effective treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among covid19 patients, across India.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Product
o By Diagnosis
o By Treatment
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- Cadila Pharmaceuticals, CELON LABS, Lifecare Innovations Pvt. Ltd., Merck Sharp & Dohme Corp., and Sun Pharmaceutical Industries Ltd.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Mucormycosis Treatment Market Report Segment
By Diagnosis
By Treatment
By End-User
Global Mucormycosis Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/mucormycosis-treatment-market